LYL-331

N/A

Report date: 2023/12/18 18:09:33

Base Information

Drug NameLYL-331
Drug Alias NameLYL331
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy
Mechanisms of ActionImmunologic cytotoxicityT lymphocyte replacementsCancer/testis antigen 1 inhibitors
TargetsCancer/testis antigen 1
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesLyell Immunopharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesLyell Immunopharma Inc
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A